1
|
Vinjamuri BP, Pan J, Peng P. A Review on Commercial Oligonucleotide Drug Products. J Pharm Sci 2024; 113:1749-1768. [PMID: 38679232 DOI: 10.1016/j.xphs.2024.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 04/21/2024] [Accepted: 04/22/2024] [Indexed: 05/01/2024]
Abstract
Oligonucleotide drug products commercially approved in the US and the EU are reviewed. A total of 20 products that includes 1 aptamer, 12 antisense oligonucleotides (ASOs), 6 small interfering ribonucleic acids (siRNAs), and 1 mixture of single-stranded and double-stranded polydeoxyribonucleotides have been identified. A typical oligonucleotide formulation is composed of an oligonucleotide with buffering agent(s), pH adjusting agents, and a tonicity adjusting agent. All the products are presented as 2.1 - 200 mg/mL solutions at pH between 6 and 8.7. Majority of the products are approved for intravenous (IV) and subcutaneous (SC) routes, with two for intravitreal (IVT), two for intrathecal (IT), and one for intramuscular (IM) routes. The primary packaging includes vials and prefilled syringes (PFS). Products approved for IV and IT administration routes and requiring >1.5 mL dose volumes are supplied in vials, while those approved for SC, IM, and IVT and requiring ≤1.5 mL dose volume are supplied in PFS. Based on the compiled dataset, we propose a generalized starting point for an oligonucleotide formulation during early phase development for IV, SC, and IT administration routes. Overall, we believe this harmonized evaluation and understanding of various oligonucleotide drug product attributes will help derive platform generalizations and allows for accelerated early phase development for first-in-human studies.
Collapse
Affiliation(s)
- Bhavani Prasad Vinjamuri
- Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States.
| | - Jiayi Pan
- Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States
| | - Paul Peng
- Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States.
| |
Collapse
|
2
|
Fiserova B, Minarik M, Nahunek M, Kysilka R, Minarik M. Improvement of oligonucleotide separation using a repetto high-performance liquid chromatography recycling approach. J Sep Sci 2024; 47:e2400252. [PMID: 38822226 DOI: 10.1002/jssc.202400252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Revised: 05/04/2024] [Accepted: 05/07/2024] [Indexed: 06/02/2024]
Abstract
A new approach for the improvement of separation of oligonucleotides by recycling ion-pairing chromatography is described. In the so-called repetto process, segments of separated compounds are sequentially returned to the inlet for multiple passages through the column without a need to pass a pump and with the possibility of detecting the level of separation between individual passages. Unlike in the recently described twin-column recycle approach in which eluents are repeatedly transferred between two separation columns, with the repetto method a single column is sufficient, and the detector is not exposed to high back pressure. The repetto principle was used for the separation of synthetic oligonucleotides, resulting in a multi-fold improvement in single nt resolution of long (> 50 nt) synthetic oligonucleotide fragments with high gas chromatography (guanine-cytosine) content > 40% and their separation from impurities of the original synthesis.
Collapse
Affiliation(s)
- Barbora Fiserova
- Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
| | | | | | | | - Marek Minarik
- Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
- Watrex Praha s.r.o., Prague, Czech Republic
| |
Collapse
|
3
|
Ozaki M, Kuwayama T, Shimotsuma M, Hirose T. Separation and purification of short-, medium-, and long-stranded RNAs by RP-HPLC using different mobile phases and C 18 columns with various pore sizes. ANALYTICAL METHODS : ADVANCING METHODS AND APPLICATIONS 2024; 16:1948-1956. [PMID: 38445900 DOI: 10.1039/d4ay00114a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/07/2024]
Abstract
Nucleic acids, which have been employed in medicines for various diseases, are attracting attention as a new pharmaceutical model. Depending on the target substances, nucleic acid medicines with various nucleic acid chain lengths (several tens of nucleotides [nt] to several thousands of nt) exist. The purification of synthesized nucleic acids is crucial as various impurities remain in the crude product after synthesis. Presently, reversed-phase high-performance liquid chromatography (RP-HPLC) represents an effective purification method for nucleic acids. However, the information regarding the HPLC conditions for separating and purifying nucleic acids of various chain lengths is insufficient. Thus, this technical note describes the separation and purification of short-, medium-, and long-stranded nucleic acids (several tens of nt to thousands of nt) by RP-HPLC with various mobile phases and octadecyl-based columns with various pore sizes, such as normal (9-12 nm), wide (30 nm), and super wide (>30 nm) pores.
Collapse
Affiliation(s)
- Makoto Ozaki
- Research and Development Department, Nacalai Tesque, Inc., Ishibashi Kaide-cho, Muko-shi, Kyoto 617-0004, Japan.
| | - Tomomi Kuwayama
- Research and Development Department, Nacalai Tesque, Inc., Ishibashi Kaide-cho, Muko-shi, Kyoto 617-0004, Japan.
| | - Motoshi Shimotsuma
- Research and Development Department, Nacalai Tesque, Inc., Ishibashi Kaide-cho, Muko-shi, Kyoto 617-0004, Japan.
| | - Tsunehisa Hirose
- Research and Development Department, Nacalai Tesque, Inc., Ishibashi Kaide-cho, Muko-shi, Kyoto 617-0004, Japan.
| |
Collapse
|
4
|
Hari Y, Fuchi Y, Yamamoto K, Ito Y. Benzo-Fused 7-Oxabicyclo[2.2.1]heptane-2,3-diol Derivatives as Universal Linkers for Solid-Phase Oligonucleotide Synthesis. SYNTHESIS-STUTTGART 2023. [DOI: 10.1055/s-0042-1751405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
AbstractIn solid-phase oligonucleotide (ON) synthesis, especially for 3′-modified ONs, a universal linker attached to a solid support is widely used. In this study, benzo-fused 7-oxabicyclo[2.2.1]heptane-2,3-diol derivatives are designed, synthesized, and evaluated as universal linkers. The designed linkers show reactivity comparable to that of a conventional universal linker for releasing the desired ONs. Additionally, these materials exhibit a more robust structure under basic conditions, as generally used in ON synthesis, and hydrophobic properties relative to the conventional universal linker. Notably, when diphenyl-substituted (terphenyl) and phenanthrene-type (PT) linkers are used, cyclic phosphodiesters derived from linker units as byproducts, which are produced by release of ONs from the linker units, are detected in the HPLC chromatograms. The PT linker is applicable to various ON syntheses using controlled pore glass (CPG) and polystyrene (PS) resins. These results demonstrate that the PT linker can serve as an alternative to conventional universal linkers.
Collapse
|
5
|
Fillon YA, Akhtar N, Andrews BI, Benstead D, Breitler S, Gronke RS, Olbrich M, Stolee JA, Vandermeersch T. Determination of Purge Factors for Use in Oligonucleotide Control Strategies. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.1c00398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yannick A. Fillon
- Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States
| | | | - Benjamin I. Andrews
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, U.K
| | | | - Simon Breitler
- F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Robert S. Gronke
- Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Martin Olbrich
- F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Jessica A. Stolee
- Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States
| | | |
Collapse
|
6
|
Kim SW, Cho YI, Jung KE. Avoiding
High‐Pressure
Problem for Modified
RNA
‐attached Polystyrene Support by
Pre‐Swelling
Using Toluene in the Oligonucleotide Synthesis. B KOREAN CHEM SOC 2021. [DOI: 10.1002/bkcs.12366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Sung Won Kim
- Research Center, Oligo CDMO, ST Pharm Siheung 15086 South Korea
- Catholic University Department of Biotechnology Bucheon 14662 South Korea
| | - Yang Il Cho
- Research Center, Oligo CDMO, ST Pharm Siheung 15086 South Korea
| | - Kyeong Eun Jung
- Research Center, Oligo CDMO, ST Pharm Siheung 15086 South Korea
| |
Collapse
|